Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
This research aims to collect real-world clinical data to evaluate the performance and safety of NeocementAE, a synthetic bone substitute used in orthopaedic surgery for bone defect treatment in adults over 18 years old. NeocementAE combines calcium phosphates with chitosan to support bone integration and regeneration. The study serves to provide clinical evidence for compliance with the European Medical Device Regulation EU 2017745 and to monitor the devices safety and effectiveness after market launch. NeocementAE is classified as a Class III medical device intended for long-term implantation by experienced orthopaedic surgeons during surgical procedures. It is primarily composed of tetracalcium phosphate and beta-tricalcium phosphate, designed to be placed in contact with bone and surrounding tissues via invasive surgery. The study observes standard clinical practice without introducing new uses or modifications to the device. Participants will be followed for one year, with data collected at four time points approximately 6 weeks, 3 months, 6 months, and if necessary, 12 months after surgery. Participants will be monitored according to local medical standards during their routine care. Clinical data includes assessments of device performance and safety at specified visits, quality of life measured by the SF-36 questionnaire at 6 weeks and 6 months, and surgeon satisfaction surveys at 6 weeks. The study aims to detect any emerging risks, misuse, or changes in device performance. Participation involves no additional risks or direct benefits beyond standard care, with follow-up lasting up to one year post-surgery.
Actively Recruiting
This observational study collects real-world clinical data to evaluate the performance and safety of Neocement4 Inject P, a synthetic bone substitute designed to enhance bone repair and regeneration. The study focuses on patients with bone defects treated according to current clinical practice, aiming to provide clinical evidence to support regulatory submission under the Medical Device Regulation EU 2017745. The study aims to monitor emerging risks and ensure ongoing safety and effectiveness of the device in typical use. Neocement4 Inject P combines tetracalcium phosphate and beta-tricalcium phosphate with chitosan and an aqueous solution enriched with citric acid and glucose. It is used to fill bony voids or gaps in the skeletal system that do not affect bone stability, applied surgically in operating rooms. Multiple units may be used depending on the lesion size. The device is expected to be partially or fully resorbed within approximately six months. No new uses, populations, or design changes are included in this post-market study. Participants will be followed for one year according to standard local medical practices, with data collected at four time points enrollment at about 6 weeks post-surgery, then at 3 months, 6 months, and if needed at 12 months. Assessments include device performance and safety, quality of life surveys, and surgeon satisfaction. There are no additional risks or direct benefits beyond routine care, and data will help maintain up-to-date information on the devices clinical use and safety profile.